UroGen Pharma Ltd. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
UroGen Pharma Ltd. (URGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $168.00 thousand for the 12-month period ending 2017-12-31, per its 20-F filed 2018-03-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2018-11-13
- UroGen Pharma Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2017-12-31 was $0.00.
- UroGen Pharma Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2017-09-30 was $0.00.
- UroGen Pharma Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2017-06-30 was $277.00K.
- UroGen Pharma Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2017-03-31 was -$109.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2018-03-15 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $277.00K derived: sum of 3 quarters · filed 2018-11-13 | $168.00K 20-F · filed 2018-03-15 |
| 2017-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $277.00K derived: sum of 2 quarters · filed 2018-11-13 | $168.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $277.00K 6-K · filed 2018-08-14 | $168.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | -$109.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $2.74M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |